Wolfe Research upgraded Edwards Lifesciences to Peer Perform from Underperform without a price target. The firm says its thesis has played out and the shares offer a more balanced risk/reward following the selloff.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW: